ERBB2 and breast cancer: The choice between either pre-operative or post-operative systemic treatment in ER positive-HER2 negative breast cancer is more difficult, as there is no direct evidence of benefit of NACT in this group [33], nor is available a targeted post-neoadjuvant treatment in those patients who do not achieve pCR.